StockUS listing USPTCTNASDAQHealthcareQuality Compounder

PTC Therapeutics Inc(PTCT) Stock Analysis | Healthcare

USD --+0.00%
Reward68High
Risk27Low
75%Data
Thin -4% profit margin · Revenue growing 101% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 4.94Bn
Reward Ratingⓘ68 High reward assessment · 75% data coverage
Top 25% of stocksView factors
Risk Ratingⓘ27 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on PTCT to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is PTC Therapeutics Inc?

, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.

AI Brief Pro

The brief on PTC Therapeutics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is PTC Therapeutics Inc?

, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 4.94B.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: High (68)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.489
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
19126,492 shares
$8.6M
0
9-12months
11,024 shares
$81k
0